CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus Comparison of one-year clinical outcomes between intravascular ultrasound-guided versus angiography-guided implantation of drug-eluting stents for left main lesions: a single-center analysis of a 1,016-patient cohort Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study Second vs. First generation drug eluting stents in multiple vessel disease and left main stenosis: Two-year follow-up of the observational, prospective, controlled, and multicenter ERACI IV registry Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions Comparison of plaque characteristics in narrowings with ST-elevation myocardial infarction (STEMI), non-STEMI/unstable angina pectoris and stable coronary artery disease (from the ADAPT-DES IVUS Substudy) Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) Cardiovascular Magnetic Resonance as a complementary method to Transthoracic Echocardiography for Aortic Valve Area Estimation in patients with Aortic Stenosis: A systematic review and meta-analysis

Original Research

JOURNAL:CBSMD Article Link

TAVR后的冠状动脉介入

CBSMD

Pre-reading


接受经导管主动脉瓣置换术(TAVR)治疗的患者的冠状动脉事件的累积风险较高,冠状动脉通路是否良好对于后续的冠脉介入是个挑战,最新一期的JACC Intervention为TAVR及后续的冠脉介入特刊


1. “Coronary Access After TAVR” 介绍了真实世界中通过CT明确的TAVR术后冠状动脉通路不良(unfavorable coronary access)患者的冠脉介入成功率数据后发现:

1)TAVR术后冠脉通路不良患者的冠脉介入成功率低于冠状动脉通路良好的患者。Evolut R/Evolut PRO 组(0.0% vs. 77.8%; p = 0.003),SAPIEN 3 组(33.3% vs. 91.4%; p = 0.003) ;

2)提出了TAVR术中有助于保持良好冠状动脉通路的技术细节。


2. “Coronary Access After TAVR With a Self-Expanding Bioprosthesis: Insights From Computed Tomography”介绍了通过多层计算机断层CT观察到的经导管心脏瓣膜(THV)中位TAVR 30天后与左、右冠脉开口的相对解剖位置。



3. Low Risk TAVR试验 "Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients"指出TAVR治疗会对低风险患者的冠状通路造成影响, 或引发主动脉瓣再干预(TAVR-in-TAVR)时的冠脉阻塞。



4. “Coronary Protection to Prevent Coronary Obstruction During TAVR:A Multicenter International Registry”则比较了TAVR术后冠脉保护的两种方案,3年随访结果显示:

1) 通过支架保护冠脉开口后的心源性死亡率显著低于导丝保护后的心源性死亡率(7.8% vs. 15.8%, adjusted hazard ratio: 0.42; 95% confidence interval: 0.14 to 1.28; p = 0.13;且通过置入支架保护的TAVR患者的明确的支架内血栓发生率不高(0.9%);

2)通过导丝保护冠脉开口的患者需要预防延迟性的冠脉闭塞(delayed coronary occlusions),发生率为4.3%。